<DOC>
	<DOCNO>NCT00078897</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development recurrence cancer . Selenium may effective prevent recurrence adenomatous colorectal polyp . PURPOSE : This randomized phase III trial study selenium see well work prevent recurrence polyp patient adenomatous colorectal polyp .</brief_summary>
	<brief_title>Selenium Prevention Adenomatous Colorectal Polyps</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare effect selenium vs placebo recurrence adenomatous colorectal polyp , term histologic type , degree dysplasia , number , size , location , patient adenomatous colorectal polyp . - Compare type , incidence , outcome side effect patient treat regimen . - Determine patient adherence long-term treatment regimen . Secondary - Determine effect regimen modification baseline blood selenium level , low-dose aspirin , selenoprotein genetic marker polymorphism ( e.g. , GPx-1 , GPx-2 , SEP15 ) - Determine effect low-dose aspirin ( 81 mg/day ) modification ornithine decarboxylase promoter genotype , toxicity slow-metabolizer genotype cytochrome p450 2C9 UT1A6 locus patient . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord use low-dose ( ≤ 81 mg/day ) aspirin ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral selenium daily . - Arm II : Patients receive oral placebo daily . In arm , treatment continue 5 years* absence disease progression unacceptable toxicity . Patients undergo follow-up colonoscopy approximately 5 years* baseline colonoscopy . NOTE : Some patient continue participation 7 half year PROJECTED ACCRUAL : A total 1,600 patient adenoma randomize study , follow second group randomization 200 patient least one advanced adenoma ( baseline ) substudy . Total planned randomization = 1,800 participant .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Polyps</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Adenomatous Polyps</mesh_term>
	<mesh_term>Selenium</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm colorectal adenomatous polyp Meets follow criterion colonoscopy ( perform within past 6 month ) : Cecum totally visualize reach At least 90 % visualization colon surface area Removed least 1 adenomatous polyp least 3 mm size procedure ( For Advanced Adenoma Substudy : Removal least 1 advanced colorectal adenomatous polyp procedure . An adenoma consider advanced 10 mm great size , and/or villous histology and/or show high grade dysplasia ) Removed 10 adenomatous polyp size endoscopy All neoplastic nonneoplastic colon polyp must completely remove ( except diminutive [ le 3 mm ] sessile rectal polyp ) For substudy , least 1 advanced adenomatous polyp define 10 mm great size and/or villous histology and/or show high grade dysplasia No prior diagnosis following : Colorectal cancer Familial adenomatous polyposis Ulcerative colitis Crohn 's disease Hereditary nonpolyposis colon cancer ( HNPCC ) , define : Histologically confirm colorectal cancer least 3 relative , 1 firstdegree relative 2 Disease occurrence least 2 consecutive generation Colorectal cancer diagnosis least 1 family member le 50 year age Patients family history colorectal cancer diagnose HNPCC allow No 1 prior segmental colon resection PATIENT CHARACTERISTICS : Age 40 80 Performance status SWOG 01 Life expectancy Not specify Hematopoietic Hemoglobin &gt; 11 g/dL WBC 3,000 11,000/mm^3 Hepatic AST ALT &lt; 2 time upper limit normal Bilirubin &lt; 2.0 mg/dL Renal Creatinine &lt; 1.9 mg/dL Cardiovascular No unstable* cardiac disease despite medication ( e.g. , diuretic digitalis ) No uncontrolled hypertension ( i.e. , systolic blood pressure ≥ 170 mm Hg and/or diastolic blood pressure ≥ 110 mm Hg ) despite medication NOTE : *Unstable define unable walk across room without chest pain shortness breath Other Not pregnant nursing Fertile patient must use effective contraception least 2 month study treatment Resident clinical center metropolitan area obtain regular health care clinical metropolitan area least 6 month year Must able swallow pills No unexpected weight loss 10 % within past 6 month No prior rheumatoid arthritis No poorly control diabetes mellitus despite medication , define : Blood sugar level ≥ 200 mg/dL half reading take within past month No invasive malignancy within past 5 year require medical excision , radiotherapy , chemotherapy except basal cell squamous cell carcinoma PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent drug regulate immune system Chemotherapy No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy No concurrent radiotherapy Surgery See Disease Characteristics Other Prior enrollment another adenoma prevention study allow Concurrent routine aspirin ( ≤ 81 mg/day ) allow No regular use nonsteroidal antiinflammatory drug ( NSAIDs ) No concurrent enrollment another research study use pharmacological cancer drug , cyclooxygenase2 inhibitor , selenium No concurrent selenium unless dosage ≤ 50 µg/day</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>colon cancer</keyword>
	<keyword>rectal cancer</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>adenomatous polyp</keyword>
</DOC>